アシネトバクター肺炎治療薬の市場規模、シェア、動向分析レポート：薬剤クラス別、投与経路別、地域別、セグメント予測、2024年～2030年

アシネトバクター肺炎治療薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のアシネトバクター肺炎治療薬市場規模は、2024年から2030年にかけて6.70%のCAGRを記録し、2030年までに4億7,096万米ドルに達する見込みです。

アシネトバクター感染症の高い発生率、抗生物質耐性の上昇、広範な研究開発、有利な政府のイニシアティブと資金提供、薬剤耐性の上昇など、いくつかの要因が市場成長を促進する要因となっています。Acinetobacter baumanniiは、入院患者の院内感染を引き起こす主要な病原体です。この病原菌は人工呼吸器関連肺炎や血流感染を引き起こします。この菌株は多剤耐性であることが報告されており、極めて急速に拡散する可能性があります。

この微生物の治療は困難であり、Acinetobacter baumanniiの多剤耐性のために妨げられています。併用療法は、この種の感染症に最も広く用いられている治療法です。アシネトバクター肺炎の治療の第一選択薬には、B-ラクタム系抗生物質、セファロスポリン系抗生物質、カルバペネム系抗生物質、フルオロキノロン系抗生物質、スルバクタム系抗生物質、スルホンアミド系抗生物質などがあります。これらの治療薬は重症度に応じて単剤または併用療法の一部として使用されます。第一選択薬が無効な場合、第二選択薬としてアミノグリコシド系、ポリミキシン系、テトラサイクリン系、グリシルサイクリン系などの抗生物質が投与されます。これらの薬剤はその副作用のために第二選択薬とされています。

アシネトバクター肺炎治療薬市場レポート・ハイライト

• セファロスポリン系薬剤クラス別セグメントは、2023年に最大の収益シェアを占めました。セフタジジムは第一選択薬として使用され、セフィデロコールは第二選択薬として使用されます。
• また、スルバクタム系セグメントでは、新たに発売されたザクデュロが予測期間中に大きなCAGRで成長すると予想されます。
• 投与経路に基づくと、非経口投与セグメントは2023年に最大の収益シェアを占めました。静脈内投与による抗生物質の迅速かつ直接的な送達は、迅速な吸収と有効性を保証し、重篤な感染症の治療に好ましい方法となっています。
• ザクデュロ（注射用スルバクタム；注射用デュロバクタム）、ポリミキシン（コリスチン）、カルバペネム、アミノグリコシドは、アシネトバクター肺炎の治療のために非経口投与される薬剤の一部です。
• 2023年には、北米が37.31%のシェアを占めました。これは、高度な医療インフラ、高い認知度、臨床試験のための広範な研究活動によるものです。
• 同地域はアシネトバクター肺炎の有病率が高く、病気の診断と治療に対する意識も高いです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 アシネトバクター肺炎治療薬市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• アシネトバクター肺炎治療薬市場分析ツール
  • 業界分析-ポーターのファイブフォース分析
  • PESTEL分析
  • 価格分析
  • パイプライン分析

第4章 アシネトバクター肺炎治療薬市場：薬剤クラスの推定・動向分析

• 世界のアシネトバクター肺炎治療薬市場：薬剤クラスのセグメントダッシュボード
• 世界のアシネトバクター肺炎治療薬市場：薬剤クラスの変動分析
• 世界のアシネトバクター肺炎治療薬市場規模と動向分析、薬剤クラス別、2018～2030年
• セファロスポリン
• フルオロキノロン
• グリシルサイクリン
• カルバペネム
• β-ラクタム系抗生物質
• スルバクタム
• アミノグリコシド
• ポリミキシン
• テトラサイクリン
• スルホンアミド
• その他

第5章 アシネトバクター肺炎治療薬市場：投与経路の推定・動向分析

• 世界のアシネトバクター肺炎治療薬市場：投与経路のセグメントダッシュボード
• 世界のアシネトバクター肺炎治療薬市場：投与経路の変動分析
• 世界のアシネトバクター肺炎治療薬市場規模と動向分析、投与経路別、2018～2030年
• 非経口
• オーラル
• その他

第6章 アシネトバクター肺炎治療薬市場：地域の推定・動向分析

• 地域の市場ダッシュボード
• 市場規模・予測、動向分析、2018年～2030年
• 北米
• 欧州
• アジア太平洋地域
• ラテンアメリカ
• 中東・アフリカ

第7章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • Pfizer Inc.
  • Merck &Co., Inc.
  • GlaxoSmithKline plc（GSK）
  • AstraZeneca plc
  • Novartis AG
  • Johnson &Johnson
  • Sanofi SA
  • Bayer AG
  • Basilea Pharmaceutica

List of Tables

• Table 1 List of key distributors and channel partners
• Table 2 List of key emerging companies'/technology disruptors/innovators
• Table 3 North America Acinetobacter Pneumonia Therapeutics Market, by country, 2018 - 2030 (USD Million)
• Table 4 North America Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
• Table 5 North America Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 6 U.S. Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
• Table 7 U.S. Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 8 Canada Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
• Table 9 Canada Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 10 Europe Acinetobacter Pneumonia Therapeutics Market, by country, 2018 - 2030 (USD Million)
• Table 11 Europe Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
• Table 12 Europe Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 13 Germany Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
• Table 14 Germany Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 15 UK Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
• Table 16 UK Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 17 France Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
• Table 18 France Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 19 Italy Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
• Table 20 Italy Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million
• Table 21 Spain Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
• Table 22 Spain Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 23 Denmark Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
• Table 24 Denmark Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 25 Sweden Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
• Table 26 Sweden Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 27 Norway Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
• Table 28 Norway Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 29 Asia Pacific Acinetobacter Pneumonia Therapeutics Market, by country, 2018 - 2030 (USD Million)
• Table 30 Asia Pacific Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
• Table 31 Asia Pacific Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 32 Japan Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
• Table 33 Japan Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 34 China Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
• Table 35 China Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 36 India Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
• Table 37 India Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 38 Australia Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
• Table 39 Australia Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 40 South Korea Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
• Table 41 South Korea Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 42 Thailand Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
• Table 43 Thailand Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 44 Latin America Acinetobacter Pneumonia Therapeutics Market, by country, 2018 - 2030 (USD Million)
• Table 45 Latin America Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
• Table 46 Latin America Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million
• Table 47 Brazil Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
• Table 48 Brazil Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 49 Mexico Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
• Table 50 Mexico Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 51 Argentina Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
• Table 52 Argentina Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 53 MEA Acinetobacter Pneumonia Therapeutics Market, by country, 2018 - 2030 (USD Million)
• Table 54 MEA Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
• Table 55 MEA Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 56 South Africa Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
• Table 57 South Africa Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 58 Saudi Arabia Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
• Table 59 Saudi Arabia Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 60 UAE Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
• Table 61 UAE Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 62 Kuwait Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
• Table 63 Kuwait Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Acinetobacter pneumonia therapeutics market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value chain-based sizing & forecasting
• Fig. 7 QFD modelling for market share assessment
• Fig. 8 Acinetobacter pneumonia therapeutics market snapshot (2023)
• Fig. 9 Acinetobacter pneumonia therapeutics market: Segment snapshot (2023)
• Fig. 10 Competitive Insights (2023)
• Fig. 11 Parent market outlook
• Fig. 12 Related/ancillary market outlook
• Fig. 13 Penetration and growth prospect mapping
• Fig. 14 Acinetobacter Pneumonia Therapeutics Market driver impact
• Fig. 15 Acinetobacter Pneumonia Therapeutics Market restraint impact
• Fig. 16 Porter's Five Forces Analysis
• Fig. 17 SWOT Analysis, By Factor (Political & legal Economic and technological)
• Fig. 18 Strategic alliance analysis
• Fig. 19 Recent developments & impact analysis, by key market participants
• Fig. 20 Key company market share analysis, 2023
• Fig. 21 Company market position analysis
• Fig. 22 Definition and scope, by drug class
• Fig. 23 Drug class market share analysis, 2023 & 2030
• Fig. 24 Segment dashboard
• Fig. 25 Global Acinetobacter Pneumonia Therapeutics Market, by drug class, 2018 - 2030 (USD Million)
• Fig. 26 Cephalosporins market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 27 Nonsteroidal Anti-inflammatory Drugs market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 28 Naproxen market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 29 Fluoroquinolone market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 30 Glycylcycline market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 31 Carbapenem market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 32 B-Lactam antibiotics market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 33 Sulbactam market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 34 Aminoglycoside market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 35 Polymyxins market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 36 Other NSAIDs market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 37 Tetracycline market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 38 Sulfonamide market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 39 Others market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 40 Definition and scope, by Route of Administration
• Fig. 41 Anatomy market share analysis, 2023 & 2030
• Fig. 42 Segment dashboard
• Fig. 43 Global Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
• Fig. 44 Parenteral market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 45 Oral market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 46 Other route market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 47 North America market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 48 U.S. market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 49 Canada market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 50 Europe market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 51 UK market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 52 Germany market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 53 Spain market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 54 France market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 55 Italy market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 56 Sweden market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 57 Denmark market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 58 Norway market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 59 Asia Pacific market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 60 China market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 61 Japan market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 62 India market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 63 Australia market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 64 South Korea market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 65 Thailand market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 66 Latin America market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 67 Brazil market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 68 Mexico market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 69 Argentina market size, & forecasts and trend analysis, 2018 to 2030 (USD Million))
• Fig. 70 Middle East and Africa market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 71 South Africa market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 72 Saudi Arabia market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 73 UAE market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 74 Kuwait market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)

Acinetobacter Pneumonia Therapeutics Market Growth & Trends:

The global acinetobacter pneumonia therapeutics market size is expected to reach USD 470.96 million by 2030, registering a CAGR of 6.70% from 2024 to 2030, according to a new report by Grand View Research, Inc. Several factors are responsible for driving market growth including a high incidence of acinetobacter infections, rising antibiotic resistance, extensive R&D, and favorable government initiatives & funding, and rising drug resistance. Acinetobacter baumannii is a major pathogen responsible for causing hospital-acquired infections in hospitalized patients. The pathogen causes ventilator-associated pneumonia and bloodstream infection. This strain of microorganisms has been reported to be multidrug-resistant and can spread extremely fast.

The treatment of this microorganism can be challenging and is hampered due to the multidrug resistance of the Acinetobacter baumannii. Combination therapy is the most widely used treatment for these kinds of infections. The first line of treatment for acinetobacter pneumonia includes drug classes, such as B-lactam antibiotics, cephalosporins, carbapenem, fluoroquinolone, sulbactam, and sulfonamide. The therapeutics are used in monotherapy or as part of combination therapy depending on the severity of illness. In case the first-line treatment is not effective, second-line antibiotics are administered, which include drug classes, such as aminoglycoside, polymyxins, tetracycline, and glycylcycline. These drugs are considered second-line due to their adverse effects.

Acinetobacter Pneumonia Therapeutics Market Report Highlights:

• The cephalosporins drug class segment accounted for the largest revenue share in 2023. Ceftazidime is used as a first-line treatment; cefiderocol is used as second-linene treatment for the disease
• In addition, the newly launched Xacduro under the sulbactam segment is expected to grow at a significant CAGR during the forecast period
• Based on the route of administration, the parenteral segment accounted for the largest revenue share in 2023. The rapid and direct delivery of antibiotics via the IV route ensures rapid absorption and efficacy and makes it the preferred method for treating severe infections
• Xacduro (sulbactam for injection; durlobactam for injection), polymyxins (colistin), carbapenems, and aminoglycosides are some of the drugs administered parenterally for the treatment of acinetobacter pneumonia
• In 2023, North America dominated with a share of 37.31% owing to the advanced healthcare infrastructure, high awareness levels, and extensive research activities for clinical trials
• The region has a high prevalence of acinetobacter pneumonia along with high awareness about disease diagnosis and treatment

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Route of Administration
• 1.3. Regional scope
• 1.4. Estimates and forecasts timeline
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased database
  • 1.6.2. GVR's internal database
  • 1.6.3. Secondary sources
  • 1.6.4. Primary research
  • 1.6.5. Details of primary research
    • 1.6.5.1. Data for primary interviews in North America
    • 1.6.5.2. Data for primary interviews in Europe
    • 1.6.5.3. Data for primary interviews in Asia Pacific
    • 1.6.5.4. Data for primary interviews in Latin America
    • 1.6.5.5. Data for Primary interviews in MEA
• 1.7. Information or Data Analysis
  • 1.7.1. Data analysis models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity flow analysis (Model 1)
  • 1.9.2. Approach 1: Commodity flow approach
  • 1.9.3. Volume price analysis (Model 2)
  • 1.9.4. Approach 2: Volume price analysis
• 1.10. List of Secondary Sources
• 1.11. List of Primary Sources
• 1.12. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug class outlook
  • 2.2.2. Route of administration outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Acinetobacter Pneumonia Therapeutics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing incidence of Acinetobacter infections
    • 3.2.1.2. Increasing prevalence of antibiotic resistance
    • 3.2.1.3. Increasing research & development and fundings
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Side effects and adverse reactions
    • 3.2.2.2. High cost of drug development
• 3.3. Acinetobacter Pneumonia Therapeutics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pricing Analysis
  • 3.3.4. Pipeline Analysis

Chapter 4. Acinetobacter Pneumonia Therapeutics Market: Drug Class Estimates & Trend Analysis

• 4.1. Global Acinetobacter Pneumonia Therapeutics Market: Drug Class Segment Dashboard
• 4.2. Global Acinetobacter Pneumonia Therapeutics Market: Drug Class Movement Analysis
• 4.3. Global Acinetobacter Pneumonia Therapeutics Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
• 4.4. Cephalosporins
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Fluoroquinolone
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Glycylcycline
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Carbapenem
  • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. B-Lactam antibiotics
  • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Sulbactam
  • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.10. Aminoglycoside
  • 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.11. Polymyxins
  • 4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.12. Tetracycline
  • 4.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.13. Sulfonamide
  • 4.13.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.14. Other
  • 4.14.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Acinetobacter Pneumonia Therapeutics Market: Route of Administration Estimates & Trend Analysis

• 5.1. Global Acinetobacter Pneumonia Therapeutics Market: Route of Administration Segment Dashboard
• 5.2. Global Acinetobacter Pneumonia Therapeutics Market: Route of Administration Movement Analysis
• 5.3. Global Acinetobacter Pneumonia Therapeutics Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
• 5.4. Parenteral
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Oral
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Other
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Acinetobacter Pneumonia Therapeutics Market: Regional Estimates & Trend Analysis by

• 6.1. Regional Market Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Mexico
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.3. Argentina
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2023
  • 7.3.4. Pfizer Inc.
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Merck & Co., Inc.
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. GlaxoSmithKline plc (GSK)
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. AstraZeneca plc
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Novartis AG
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Johnson & Johnson
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Sanofi S.A.
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. Bayer AG
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Product benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. Basilea Pharmaceutica
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Product benchmarking
    • 7.3.12.4. Strategic initiatives